ChemistrySelect · 2024 · 10 citations · 19 references
PharmacyMedicinal ChemistryPharmacologyChemotherapyDrug DiscoveryPharmacokinetics Of Anticancer AgentsOncology PharmacologyPharmacokinetics Of Anticancer DrugsTyrosine Kinase InhibitorsAnticancer ActivityAnticancer ChemotherapyAnticancer Compound ScreeningDocking StudiesEgfr InhibitionQuinoline SynthesisTyrosine Kinase InhibitionTyrosine Kinase Receptors
Abstract We have presented the synthesis of some new quinoline linked fused isoxazoles via copper (I) catalyzed azide alkyne cycloaddition (CuAAC) followed by intramolecular C−H arylation of isoxazole ring using PdCl 2 (PPh 3 ) 2 catalyst. All the synthesized compounds were investigated for anticancer activity against three human breast cancer cell lines such as MCF‐7, MDA‐MB‐468 and MDA‐MB‐231 using MTT assay and 5‐fluorouracil (5‐FU) was used as a standard drug. In this study, three compounds were exhibited greater activity than reference drug 5‐FU against three cell lines which further screened for in vitro tyrosine kinase EGFR inhibition and molecular docking studies by taking EGFR protein as the target. Finally, insilico pharmacokinetic profile of the same compounds was obtained using SWISSADME where two compounds following Lipinski, Ghose, Veber, Egan, and Muegge rules.
19
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Jin H. Park, Yingting Liu, Mark A. Lemmon et al. · Biochemical Journal · 2012 · 403 citations · Full text
Medicine, Oncology, Pharmacology +17
Comprehensive review on current developments of quinoline-based anticancer agents
Shweta Jain, Vikash Chandra, Pankaj Jain et al. · Arabian Journal of Chemistry · 2016 · 385 citations · Full text
Paul L. Nguyen, Arnab Chakravarti, Dianne M. Finkelstein et al. · Journal of Clinical Oncology · 2005 · 241 citations · Full text
Medicine, Radiation Oncology, Central Nervous System Radiation Oncology +11